Baxdrostat vs Lorundrostat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline
Baxdrostat · Baxfendy
Marketed by AstraZeneca and partners
NCT06034743 · Phase 3 · completed
The trial randomized 794 participants to baxdrostat or matching placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Both prespecified primary blood-pressure endpoints were met at Week 12: the reduction in seated systolic blood pressure was greater with 2 mg and 1 mg baxdrostat than with placebo, with p<0.0001 for each comparison.
Next expected readout: December 2026 · NCT07222917 (registry estimate)
Reported efficacy
Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy (Baseline to week 12): Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001). (met)
Result source: NCT06168409
Lorundrostat
Developed by Mineralys Therapeutics and partners
NCT05769608 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled trial in 285 patients with uncontrolled hypertension that measured 24-hour ambulatory systolic blood pressure, the standard efficacy measure for this disease. The 50 mg lorundrostat dose lowered ambulatory blood pressure significantly more than placebo at week 12.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) (met)
Result source: NCT06153693
Results for Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Baxdrostat | Lorundrostat |
|---|---|---|
| Seated SBP, change | -15.7 vs -5.8−9.9 vs placeboNCT060347437 other results
| —Not posted · NCT06153693 |
| 24-hour ambulatory SBP, change | -16.6 vs -2.6−14 vs placeboNCT06168409 | —Not posted · NCT06153693 |
| Seated DBP, change | -6.9 vs -3−3.9 vs placeboNCT060347434 other results
| —Not posted · NCT06153693 |
Seated SBP, change
- Baxdrostat
- -15.7 vs -5.8−9.9 vs placeboNCT06034743
7 other results
- -14.5 vs -5.8 NCT06034743
- -3.7 vs 1.4 NCT06034743
- -15.2 vs -5.4 NCT06034743
- -14.9 vs -4.7 NCT06168409
- -11.6 vs -2.4 NCT06168409
- -12.1 vs -1.1 NCT06168409
- -14.5 vs -5.4 NCT06034743
- Lorundrostat
- —Not posted · NCT06153693
24-hour ambulatory SBP, change
- Baxdrostat
- -16.6 vs -2.6−14 vs placeboNCT06168409
- Lorundrostat
- —Not posted · NCT06153693
Seated DBP, change
- Baxdrostat
- -6.9 vs -3−3.9 vs placeboNCT06034743
4 other results
- -7.6 vs -2.6 NCT06168409
- -6.1 vs -0.5 NCT06168409
- -5.4 vs 0.1 NCT06168409
- -6.3 vs -3 NCT06034743
- Lorundrostat
- —Not posted · NCT06153693
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Baxdrostat: 3 of 4 rows · Lorundrostat: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Baxdrostat | Lorundrostat |
|---|---|---|
| Dropout rate | 10.9%2 mga NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results—2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 7.2%1 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 5.5%2 mg NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 6.3%2 mg NCT06336356 · Phase 2 · registry result, not featured evidence | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Discontinued due to AEs | —2 mga NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results—2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —1 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 —2 mg NCT06336356 · Phase 2 · registry result, not featured evidence | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Serious AEs | 3.4%2 mga NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results2.3%2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 4.8%2 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 1.9%1 mg NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 0.9%2 mg NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 0%2 mg NCT06336356 · Phase 2 · registry result, not featured evidence | 3.4% NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Most frequent reported AEs | 2 mga hyperkalaemia 11.7% (placebo 2.7%) hyponatraemia 3.8% (placebo 0.8%) muscle spasms 3.8% (placebo 0.4%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 show 5 more results2 mg hyperkalaemia 9.9% (placebo 2.7%) hyponatraemia 3.5% (placebo 0.8%) nasopharyngitis 1.7% (placebo 2.3%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 2 mg hyperkalaemia 16.1% (placebo 2.7%) hyponatraemia 11.3% (placebo 0.8%) muscle spasms 6.5% (placebo 0.4%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 1 mg hyperkalaemia 6.1% (placebo 2.7%) nasopharyngitis 3% (placebo 2.3%) upper respiratory tract infection 2.7% (placebo 3.8%) NCT06034743 · Phase 3 · monotherapy · Hypertension · phase 3 2 mg hyperkalaemia 10.2% (placebo 2.8%) headache 5.6% (placebo 2.8%) hypotension 4.6% (placebo 0%) NCT06168409 · Phase 3 · monotherapy · Hypertension · phase 3 2 mg dizziness 6.3% (placebo 6.3%) nausea 6.3% (placebo 0%) vomiting 6.3% (placebo 0%) NCT06336356 · Phase 2 · registry result, not featured evidence | hyperkalaemia 15.5% (placebo 3.5%) glomerular filtration rate decreased 10.3% (placebo 3.5%) hyponatraemia 5.2% (placebo 5.3%) NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Baxdrostat
show 7 more results
show 4 more results
show 1 more result
Lorundrostat
Chronic Kidney Disease
Shared mechanism: Aldosterone synthase (CYP11B2) · full Chronic Kidney Disease pipeline
Baxdrostat · Baxfendy
Marketed by AstraZeneca and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07222917 (registry estimate)
No aligned efficacy figure on record for this race.
Lorundrostat
Developed by Mineralys Therapeutics and partners
NCT06150924 · Phase 2 · completed
Explore-CKD was a randomized, double-blind, placebo-controlled, two-period crossover Phase 2 trial of lorundrostat 25 mg on top of an SGLT2 inhibitor in about 60 patients with hypertension and albuminuric chronic kidney disease. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure at week 4: -7.5 mmHg (p=0.0024), and the sponsor states the trial met the primary endpoint. Sources: CT.gov posted results and the Mineralys press release filed on SEC Form 8-K.
Reported efficacy
Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 (Baseline to Week 4): Automated office systolic blood pressure at week 4: lorundrostat 25 mg -9.25 mmHg vs placebo -1.76 mmHg (CT.gov LS means, n=58 per period); placebo-adjusted -7.5 mmHg (p=0.0024) (Mineralys release, 17 Jun 2025, SEC 8-K). (met)
Result source: NCT06150924
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Baxdrostat | Lorundrostat |
|---|---|---|
| Kidney composite outcome | —Trial running · NCT06268873 | —Not reported |
| UACR, % change | —Trial running · NCT06268873 | —Not reported |
| eGFR slope | —Trial running · NCT06268873 | —Not reported |
| Haemoglobin, change | —Trial running · NCT06268873 | —Not reported |
Kidney composite outcome
- Baxdrostat
- —Trial running · NCT06268873
- Lorundrostat
- —Not reported
UACR, % change
- Baxdrostat
- —Trial running · NCT06268873
- Lorundrostat
- —Not reported
eGFR slope
- Baxdrostat
- —Trial running · NCT06268873
- Lorundrostat
- —Not reported
Haemoglobin, change
- Baxdrostat
- —Trial running · NCT06268873
- Lorundrostat
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Baxdrostat: registry results are on file for Chronic Kidney Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Baxdrostat: 0 of 4 rows · Lorundrostat: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lorundrostat |
|---|---|
| Dropout rate | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Discontinued due to AEs | — NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Serious AEs | 3.4% NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
| Most frequent reported AEs | hyperkalaemia 15.5% (placebo 3.5%) glomerular filtration rate decreased 10.3% (placebo 3.5%) hyponatraemia 5.2% (placebo 5.3%) NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lorundrostat
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Baxdrostat's landscape · Lorundrostat's landscape